DIRS.INFO The most relevant business & tech news

☆ Many people using GLP-1s for weight loss stop treatment too soon, research shows, and results are not one-size-fits-all
▼ + stars: | 2024-05-21 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +8 min

Professional organizations have set this as a guideline for when to reassess whether a treatment is providing clinically meaningful weight loss. People who met with their providers less frequently – and those living in underserved regions with broader health inequities – were more likely to discontinue GLP-1 treatment sooner. But using GLP-1 treatments are still an investment in many ways. These injected medications, called GLP-1 agonists, are in high demand because they have proved to be so effective for weight loss. And experts warn that the GLP-1 treatment process can be different for everyone.

Persons: ”, Disha, Wegovy, Jody Dushay, Beth, There’s, Razia Hashmi, ” Hashmi, it’s, “, Dr, Sanjay Gupta, ” Narang, ” Dushay Organizations: CNN, Endeavor Health, Beth Israel Deaconess Medical Center, Harvard Medical School, Shield, Dandelion Health, CNN Health, “ Locations: Chicago, –, GLP

☆ What the results of Wegovy’s longest clinical trial yet show about weight loss, side effects and heart protection
▼ + stars: | 2024-05-13 | by ( Meg Tirrell | ) edition.cnn.com time to read: +10 min

CNN —New analyses of the longest clinical trial yet of the weight-loss drug Wegovy are shedding light on how quickly it helps people lose weight, how long they sustain that weight loss and how safe the medicine is over four years of use. A previous clinical trial showed even greater average weight loss for Wegovy: about 15% on average over 68 weeks, compared with 2.4% for people who got a placebo. It was sustained for up to four yearsThe results showed that the 10% average weight loss for people using Wegovy was sustained for up to 208 weeks, or four years. Patients stayed on the medicine while they sustained the weight loss. Almost 23% of people on Wegovy lost at least 15% of their body weight, compared with 1.7% on a placebo.

Persons: Wegovy, –, ”, Harlan Krumholz, Dr, Donna Ryan, Eli Lilly, wasn’t, they’d, Daniel Drucker, it’s, John Deanfield, Krumholz, Drucker, GLP, Sanjay Gupta Organizations: CNN, Yale University, Yale New Haven Hospital, drugmaker, Nordisk, Novo Nordisk, European, Obesity, Nature, Pennington Biomedical Research, University of Toronto, University College London, CNN Health Locations: Baton Rouge , Louisiana, Novo

☆ ‘Ozempic babies’: What the science says on whether GLP-1s lead to surprise pregnancies, and their safety if they do
▼ + stars: | 2024-05-08 | by ( Mira Cheng | Meg Tirrell | ) edition.cnn.com time to read: +12 min

“I was depressed, severely depressed for that whole time.”Five months earlier, in October 2022, Bentley had started taking Mounjaro for weight loss. Ozempic uses the active ingredient semaglutide, and Wegovy is the version approved for weight loss. Mounjaro uses tirzepatide, which also targets a second hormone called GIP, and Zepbound is its brand name for weight loss. Safety in pregnancyEven as GLP-1 medicines may increase fertility, little is known about their safety during pregnancy. “It’s kind of like heart failure or sleep apnea,” he said, referring to conditions for which GLP-1 drugs have recently shown positive results.

Persons: CNN — Catera Bentley, Bentley, ”, “, ” Bentley, she’d, —, ‘, ’ Bentley, Jody Dushay, Dushay, Catera Bentley, Ivy, Daniel Drucker, ” Drucker, they’re, Drucker, Eli Lilly, ” Dushay, haven’t, That’s, Anuja Dokras, Dokras, Melanie Cree, Cree, PCOS, aren’t, Eli Lilly’s, Daniel Skovronsky, ” Skovronsky, Dr, Sanjay Gupta, it’s, Mounjaro Organizations: CNN, Beth Israel Deaconess Medical Center, Harvard Medical School, University of, Mount Sinai, Novo Nordisk, Zepbound, US Centers for Disease Control, University of Pennsylvania, PCOS, Children’s Hospital, National Institutes of Health, CNN Health Locations: Steele , Alabama, Mount, United States, Children’s Hospital Colorado, —, Colorado

☆ FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
▼ + stars: | 2024-04-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The Federal Trade Commission on Tuesday said it is challenging hundreds of alleged "junk" patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk's blockbuster drugs Ozempic, Saxenda and Victoza. The FTC issued letters to 10 companies, warning them that certain drug patents were improperly listed. Many of the drug patents are for Type 2 diabetes, along with asthma and inhalers for chronic obstructive pulmonary disease, or COPD. Generic drugmakers can only launch cheaper versions of a branded drug if the patents have expired or are successfully challenged in court. The FTC first challenged dozens of branded drug patents last fall, leading three drugmakers to comply and delist their patents with the FDA.

Persons: Novo, Boehringer, Lina Khan, Biden, drugmakers, Joe Biden's Organizations: Federal Trade Commission, FTC, Novo Nordisk, AstraZeneca, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, Amphastar Pharmaceuticals, Food and Drug Administration, FDA Locations: U.S

☆ Diplomats Head to Saudi Arabia for New Talks About War in Gaza
▼ + stars: | 2024-04-28 | by ( Vivek Shankar | ) www.nytimes.com time to read: +3 min

By Saturday, the heat had significantly eased and the forecast was for more moderate temperatures in coming days. Mr. Fayyad was displaced with his wife and only daughter from Khan Younis, where they lived and owned a pharmacy. Nearly two million Palestinians in Gaza were forced to flee their homes under Israeli bombardment and military evacuation orders. Parents across the Gaza Strip are relying on water to keep their children cool when it is already not easy to get. He added: “The tent, the heat wave, and the horror of this war are all a nightmare.

Persons: ”, Mohammed Fayyad, Fayyad, Julia, Mr, Khan Younis, Mohammed Abu Hatab, “, Abu Hatab Locations: Gaza, Al

☆ Patients Hate ‘Forever’ Drugs. Is Wegovy Different?
▼ + stars: | 2024-03-24 | by ( Gina Kolata | ) www.nytimes.com time to read: +1 min

Most people, study after study shows, don’t take the medicines prescribed for them. It doesn’t matter what they are — statins, high blood pressure drugs, drugs to lower blood sugar, asthma drugs. Either patients never start taking them, or they stop. Though it’s still early days, and there is a paucity of data on compliance with the new drugs, doctors say they are noticing another astounding effect: Patients seem to take them faithfully, week in and week out. A national survey showed that when people were told they would gain weight back if they stopped taking the drugs, most lost interest in starting them.

Persons: don’t, nonadherence, Wegovy, it’s

☆ Eli Lilly taps Amazon Pharmacy to help deliver weight loss drug Zepbound, other medicines to patients
▼ + stars: | 2024-03-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly on Wednesday said Amazon Pharmacy will help send certain prescription drugs, including the red-hot weight loss treatment Zepbound, to patients' homes through the drugmaker's new direct-to-consumer program. The website, LillyDirect, connects people with an independent telehealth company that can prescribe certain drugs if they are eligible. LillyDirect plans to expand the medicines it offers and the companies it partners with in the future, Eli Lilly said. Amazon Pharmacy offers free two-day deliveries to patients with an Amazon Prime membership, which will also apply if they use LillyDirect. But he told CNBC that Eli Lilly expects Amazon Pharmacy and Truepill to have similar processing and shipping times.

Persons: Eli Lilly, Eli Lilly's, Frank Cunningham, Cunningham, Truepill, John Love, We're, Lilly Organizations: Amazon Pharmacy, Amazon, CNBC Locations: U.S

☆ How to access the new weight loss drugs
▼ + stars: | 2024-02-15 | by ( Andrea Kane | ) edition.cnn.com time to read: +7 min

(CNN) — By now, it is pretty clear that the new weight loss and diabetes medications have achieved blockbuster status. Unlike previous weight loss medications, they are pretty effective at helping people lose weight and keep it off — between around 15% to 20% of body weight — with relatively few side effects (although some people can’t tolerate them, and a fraction of patients experience more severe side effects). Zepbound, the newly approved weight loss drug from Eli Lilly, may be easier to find. “Otherwise, some physicians are prescribing older, generic weight loss medications that can be helpful for some patients.”These drugs are not right for everyoneFor many people, the cultural pressure to look a certain way is high. And join us next week on the Chasing Life podcast when we talk to WeightWatchers CEO Sima Sistani about whether these new weight loss drugs really signal the end of diet culture.

Persons: Sanjay Gupta ”, Eli Lilly, Goldman Sachs, Meg Tirrell John Nowak “, Meg Tirrell, Sanjay Gupta, ” Tirrell, “, ” Eli Lilly, Tirrell, ”, Sima Sistani Organizations: CNN, —, Trilliant Health, Novo Nordisk, US Food and Drug Administration, “, Nordisk, ”

☆ U.S. Makes Initial Offers in Medicare Drug Price Negotiations
▼ + stars: | 2024-02-01 | by ( Noah Weiland | More About Noah Weiland | ) www.nytimes.com time to read: +2 min

Why It Matters: The price offers kick off negotiations. The initial round of price offers is a key step in the negotiation process. The price negotiation program was created by the Inflation Reduction Act, the climate, tax and health care package that President Biden signed into law in 2022. Additional medications will be chosen for price negotiations in the coming years. A federal judge in Delaware heard arguments on Wednesday in a case brought by AstraZeneca, the maker of a diabetes drug that was selected for price negotiations.

Persons: ”, Andrew W, Mulcahy, Biden, Mr, drugmakers Organizations: Biden, RAND Corporation, Medicare, U.S . Chamber, Commerce, AstraZeneca Locations: Delaware

☆ FDA finds new manufacturing lapses at Eli Lilly plant
▼ + stars: | 2024-01-19 | by ( ) www.cnbc.com time to read: +4 min

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured in Branchburg, New Jersey, March 5, 2021. U.S. inspectors recently uncovered new manufacturing problems at an Eli Lilly plant that has been under scrutiny by federal investigators, according to government records obtained by Reuters. They included problems in tracking manufacturing process and quality controls, as well as lapses in its calibration of equipment and failure to properly maintain facilities and equipment, the inspection report shows. Yet the Indianapolis-based drugmaker has been cited multiple times for manufacturing problems at its U.S. plants over the last few years, Reuters has reported. Three regulatory experts who reviewed the new inspection report described the most recent lapses as serious.

Persons: Eli Lilly, Lilly, Steven Lynn, Lynn Organizations: Company, U.S, Reuters, The, The U.S . Food, Drug, FDA, U.S . Department of Justice, Justice Department, Manufacturing Locations: Branchburg , New Jersey, The U.S, Lilly's, , New Jersey, U.S, Indianapolis

COVID-19 is leading hospital admissions among the respiratory viruses, according to the U.S. Centers for Disease Control and Prevention. Last week, 25 U.S. states had high or very high levels for respiratory illnesses with fever, cough and other symptoms. Since the beginning of October, there have been at least 16 million illnesses, 180,000 hospitalizations, and 11,000 deaths from flu so far this season. With vaccination rates low, what can you do to protect yourself from respiratory viruses, including influenza, COVID-19 and RSV? That’s important to see if you need one of the medicines that can help prevent severe illness: Paxlovid for COVID-19 and Tamiflu for flu.

Persons: you’ve, Jennifer Sonney, Sonney, ” Sonney Organizations: U.S . Centers for Disease Control, CDC, HOME, University of Washington School of Nursing, National Association of Pediatric, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S, United States, Seattle, COVID

BAINBRIDGE, Ga. (AP) — Some local residents and an animal-rights group are protesting plans for a monkey-breeding facility in southwest Georgia. Political Cartoons View All 253 ImagesThe Bainbridge facility would provide a domestic source of monkeys to offset imports, the company said. “PETA urges Bainbridge officials to withdraw their support and shut down this project before a shovel hits the dirt," she wrote. The company and local officials said the nonprofit and community's concerns are baseless. Local officials in December agreed to property tax breaks for the project — waiving them for the first 10 years and then gradually decreasing tax breaks until they end after 20 years.

Persons: didn’t, Charles River, we’d, ” Ted Lee, Lisa Jones, Engel, ” Jones, Bainbridge, Rick McCaskill, ” McCaskill Organizations: Council, Medicine, Charles River Laboratories, PETA, Development Authority of, Local Locations: BAINBRIDGE, Ga, Georgia, Bainbridge, Cambodia, Brazoria County , Texas, Houston, U.S, Development Authority of Bainbridge & Decatur County

☆ Israel and Hamas have agreed deal on medicine for hostages, aid to Gaza, Qatar says
▼ + stars: | 2024-01-16 | by ( Tara John | ) edition.cnn.com time to read: +3 min

CNN —Qatar says it has brokered a deal between Israel and Hamas that will see medicines delivered to Israeli hostages in Gaza in exchange for the delivery of medicine and humanitarian aid to Palestinian civilians. The medications and aid will leave Doha on Wednesday and head to Egypt before being transported to Gaza, the ministry added. The medicine is destined for more than 40 hostages thought by Israel to need it, according to the official, who also said that Hamas only agreed to the deal if more medicine was sent to hospitals and Palestinians in Gaza. Throughout the war, Israel has allowed a limited amount of aid and medicines to enter Gaza but far more is needed, humanitarian groups say. The United Nations has complained that Israel has been rejecting missions to deliver supplies to northern Gaza.

Persons: Menahem Kahana, David Barnea, Cross Organizations: CNN, Hamas, “, Qatari Ministry of Foreign Affairs, Doha, Getty, of Health, UNICEF, Al, Aqsa, Prime Minister’s, International Committee, United Nations, UN Locations: Qatar, Israel, Gaza, Egypt, Israeli, AFP, British, Qatari

☆ The CEO of an A16z-backed healthcare startup is pitching a better way to save money on obesity care
▼ + stars: | 2023-12-29 | by ( ) www.businessinsider.com time to read: +8 min

Boyarsky Pratt said about 35% of Knownwell's patients come for primary care, while the rest see the company's providers for their metabolic health. They can prescribe GLP-1 drugs, but they're just one tool the company uses to treat obesity, Boyarsky Pratt said. It's also planning to partner with more health systems to help them expand access to weight care. It partners with one large system in Massachusetts now, but Boyarsky Pratt declined to disclose which one. "The data shows that the earlier patients get into a comprehensive treatment, the better for the long-term course of the disease," Boyarsky Pratt said.

Persons: —, Brooke Boyarsky Pratt, Andreessen Horowitz, Boyarsky Pratt, Knownwell, Angela Fitch, Berkadia, Fitch, Needham, Boyarsky Platt, they'd, Michael Siluk, It's Organizations: Service, Business, GLP, BMI, Medicare, Obesity Medicine Association . Obesity Medicine, University of Pennsylvania, Harvard Business School, Berkshire Hathaway, Obesity Medicine Association, Weight, Flare Capital Partners, Staff, Getty, American Academy of Pediatrics Locations: Boston, GLP, Massachusetts, Knownwell, Needham , Massachusetts, telehealth

☆ Maker of Wegovy, Ozempic showers money on U.S. obesity doctors
▼ + stars: | 2023-12-01 | by ( ) www.reuters.com time to read: +23 min

Novo spent at least $25.8 million over the past decade on U.S. medical professionals to promote its two obesity drugs, Wegovy and Saxenda, the analysis found. Jastreboff has also worked on clinical trials of obesity drugs for Eli Lilly, which markets a Wegovy competitor. Some doctors said Novo’s payments exemplify how the flood of industry money can dominate decision-making about care and coverage. Government pharmacy officer Solaru said her agency concluded that the new obesity drugs could be cost-effective by preventing other weight-related diseases and boosting workplace productivity. In January, the personnel office told its health plans they must cover at least one GLP-1 obesity drug for 8 million workers, retirees and family members.

Persons: Lee Kaplan, Kaplan, ”, gastroenterologist, He’s, Novo, Donna Ryan, Ryan, “, ” Kaplan, ” Novo, Robert Lustig, “ I’m, Lustig, They’re, Ania, ” Jastreboff, Jastreboff, Eli Lilly, Lilly’s Zepbound, Lilly, ” Lilly, Novo’s, Ayana, Sanders, Arthur Kellermann, ” Kellermann, mouthpieces, ’ ”, “ I'm, Jamy Ard, Ard, Dele, ” Solaru, ” Ryan, Scott Kahan, Kahan, Solaru, Christine Gallagher, Wegovy, Rebekah Carl, Carl, Jen Wexler, gaunt, Wexler Organizations: Novo Nordisk, Dartmouth, Nutrition Institute, Massachusetts General Hospital, Harvard Medical School, Reuters, Cambridge, Obesity Society, U.S ., Management, Reuters . Pharmaceutical, ”, U.S, United, National Health Service, University of California, U.S . Food, Drug Administration, Doctors, Wegovy’s, BMI, Yale University’s Center, Weight Management, Wall Street, American Medical Association, Rutgers University’s School of Public Health, Affordable, . Pharmaceutical, Companies, Uniformed Services University of Health Sciences, Wake Forest University, Wake Forest Baptist Health Weight Management, Obesity, Pennington Biomedical Research, U.S . National Institutes of Health, Personnel Management, Coalition, STOP, George Washington University, Novo Locations: CAMBRIDGE, Massachusetts, Boston, U.S, Novo, Danish, United States, Louisiana, San Francisco, Wegovy, Pennington, Baton Rouge , Louisiana, Government, New Columbia , Pennsylvania, Florida

In 2019, a non-governmental organization set up the camp's health post where Aliyu's ninth child, Hauwa, was delivered in 2021. "There are no special arrangements for pregnant women in IDP and refugee camps [in Nigeria]. But for most of the 64 women recorded in the camp's birth register this year, these costs are prohibitive. Nigeria's Federal Ministry of Health oversees health for the country (including provisions provided by the Commission). He tells CNN: "Women's Health services were prioritized and featured strongly in the programs designed to the needs of internally displaced women."

Persons: Aisha Aliyu, Abba, Aliyu, Aisha, Liyatu Ayuba, Ayuba, Fatima Mahmood Jibirilla, Isa Umar, Umar, they've, doesn't, Dr Charles Nzelu, Dolapo Fasawe, Fasawe, Nzelu, Iko Ibanga, Osagie, Ehanire, Ibanga Organizations: CNN, Walden University, Camp, Camp Management, Aliyu, Nigeria's Federal Ministry of Health, Commission for Refugees, Migrants, Commission, antenatal, Capital Territory, Territory's, Environmental Services, FCT Health Services, Federal Ministry of Health, Ministry, Pro Health, Federal Capital Territory, Health, Pro Health International, Union, National Primary Health Care Development Agency, Ministry of Health, National Assembly Locations: Abuja, Nigeria, Nigeria's, Wala, Borno State, Maiduguri, Haram, Durumi, Africa, Nigerian, Borno, Adamawa

The full benefit for these Indian manufacturers will not be immediate, said Peter DeYoung, CEO of Piramal Pharma Solutions. Nimgaonkar said Indian CDMOs need to do more to ensure their reputation on quality standards matches Western and Chinese ones. The Indian CDMOs told Reuters that their facilities are routinely inspected by the FDA. Aragen counts seven of the 10 biggest pharma companies as clients, he said, declining to name them. "New biotechs are deciding to put eggs in both the Indian and China baskets from the start," Subramanian said.

Persons: Trump, Tommy Erdei, Ashish Nimgaonkar, Nimgaonkar, Sai, Peter DeYoung, Helen Chen, CDMOs, Piramal, DeYoung, Ramesh Subramanian, Subramanian, Maggie Fick, Andrew Silver, Michele Gershberg, Catherine Evans Organizations: Jefferies, Glyscend Therapeutics, Reuters, Sciences, Piramal Pharma, Sai Life Sciences, Western pharma, Piramal Pharma Solutions, L.E.K, Consulting, pharma, U.S . Food, Drug Administration, FDA, Thomson Locations: China, India, SHANGHAI, HYDERABAD, U.S, Shanghai, United States, London, Hyderabad

☆ How well-off Brits still buy Ozempic online for weight loss
▼ + stars: | 2023-11-18 | by ( Maggie Fick | ) www.reuters.com time to read: +12 min

NHS diabetes patients – including Gradwell, who went for weeks without full medication – pay nothing for their medication. The shortage persists even after Ozempic's manufacturer Novo Nordisk (NOVOb.CO) launched Wegovy, a semaglutide drug solely for weight loss, in September. Rightangled told Reuters it is within its rights to continue to prescribe Ozempic for weight loss. Two had stopped offering it for weight loss by October, but Rightangled continued to make it available as of Nov. 17, Reuters found. He said his oncologist said that while he could not prescribe Ozempic, it would be good for his health if he took it for weight loss.

Persons: Kim Gradwell, –, John, it's, Rightangled, Gradwell, Penny Ward, I've, Abdullah Sabyah, Ward, Juniper, Ben, Doctors, Novo, Ozempic, semaglutide, prescribers, Rightangled's Sabyah, Tyne wasn't, Gradwell's, Yaasir Mamoojee, We've, Maggie Fick, Marine Strauss, Charlotte Van Campenhout, Chad Terhune, Sara Ledwith, Josephine Mason Organizations: Diabetes, National Health Service, Novo Nordisk, King's College, Department of Health, Social Care, John, Reuters, Oxford University ., NHS, Alliance Healthcare, Alliance, Diabetes UK, NICE, semaglutide, Oxford University, General Pharmaceutical Council, Tyne, Thomson Locations: Dudley , North Tyneside, Britain, Novo, United States, London, U.S, England, Europe, Ozempic, Newcastle, Brussels, Los Angeles

LONDON (AP) — Britain's medicines regulator has authorized the world's first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the crippling disease in the U.K. The agency approved the treatment for patients with sickle cell disease and thalassemia who are 12 years old and over. Casgevy is currently being reviewed by the U.S. Food and Drug Administration; the agency is expected to make a decision early next month, before considering another sickle cell gene therapy. Millions of people around the world, including about 100,000 in the U.S., have sickle cell disease. Scientists believe being a carrier of the sickle cell trait helps protect against severe malaria.

Persons: ”, Helen O'Neill Organizations: Medicines and Healthcare Regulatory Agency, Vertex Pharmaceuticals, CRISPR Therapeutics, Helen O'Neill of University College London, Medicines, U.S . Food, Drug Administration, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: Europe, CRISPR, South Asian, Britain, U.S, Africa, India, Eastern

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. The company declined to comment on the plans but news conferences are planned in Alzey, where sources say the plant will be built, and Berlin on Friday. Other people familiar with the plans told Reuters that at least 1,000 jobs would be created. Eli Lilly said it would unveil "far-reaching investment plans" at Friday's news conference, which will be attended by Germany's economy and health ministers. Mounjaro's success helped Lilly post a 37% gain in third-quarter revenues to $9.5 billion, topping Wall Street estimates.

Persons: Eli Lilly, Mike Segar, Mounjaro, TSMC, Lilly's, Lilly, Rene Wagner, Klaus Lauer, Andreas Rinke, Ludwig Burger, Thomas Escritt, Madeline Chambers, Miranda Murray, Christina Fincher Organizations: Company, REUTERS, Basf, Reuters, BASF, U.S ., U.S, Intel, European Union, Novo Nordisk, U.S . Food, Drug Administration, Thomson Locations: Branchburg , New Jersey, BERLIN, Germany, Alzey, Berlin, U.S, Ukraine, European, Indianapolis, Danish, Eisai

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing RightsBERLIN, Nov 15 (Reuters) - U.S. pharma company Eli Lilly (LLY.N) plans an investment in the single-digit billion dollar range in a new plant in western Germany, people familiar with the matter told Reuters after the company called a news conference for Friday. Eli Lilly said it would unveil "far-reaching investment plans" at Friday's news conference, which will be attended by Germany's economy and health ministers. Mounjaro's success helped Lilly post a 37% gain in third-quarter revenues to $9.5 billion, topping Wall Street estimates. The group's market value has ballooned to around $580 billion, up more than 65% so far this year.

Persons: Eli Lilly, Mike Segar, Mounjaro, TSMC, Lilly's, Lilly, Rene Wagner, Klaus Lauer, Ludwig Burger, Thomas Escritt, Chizu Nomiyama, Jane Merriman Organizations: Company, REUTERS, Rights, . pharma, Reuters, U.S ., U.S, Intel, European Union, Novo Nordisk, U.S . Food, Drug Administration, Thomson Locations: Branchburg , New Jersey, Germany, Rhineland, Palatinate, U.S, Ukraine, European, Indianapolis, Danish, Eisai

☆ Zepbound: The newest obesity medication explained by an expert
▼ + stars: | 2023-11-14 | by ( Katia Hetter | ) edition.cnn.com time to read: +8 min

CNN —The US Food and Drug Administration approved the medication Zepbound last week to treat chronic obesity. Tirzepatide joins a similar medication called semaglutide that was also initially developed for diabetes treatment under the name Ozempic and has since been approved to treat obesity under the name Wegovy. Studies on both have shown high effectiveness in treating diabetes and obesity. The injectable medication Zepbound, manufactured by Eli Lilly, was approved by the FDA on November 8 to treat chronic obesity. Note that technically, the versions of the medicines someone needs for obesity treatment are Zepbound and Wegovy.

Persons: Eli Lilly, Tirzepatide, —, Leana Wen, Wen, Zepbound, Ozempic Organizations: CNN, Food and Drug Administration, George Washington University Milken Institute School of Public Health, FDA, The New England, of Medicine, JAMA, Novo Nordisk, semaglutide, BMI Locations: The, tirzepatide, Wegovy

☆ Wegovy Is Shown to Reduce Risk of Heart Attacks and Strokes in Some Patients
▼ + stars: | 2023-11-11 | by ( Dani Blum | More About Dani Blum | ) www.nytimes.com time to read: +1 min

A pivotal new study suggests that the weight loss drug Wegovy cut the risk of heart attack, stroke or death from cardiovascular issues by 20 percent among overweight or obese people with heart disease — a striking benefit that could change the standard of care for these patients. “We’ve just identified a new best practice,” said Dr. Clyde Yancy, chief of the division of cardiology at Northwestern Medicine, who was not involved with the study. Drug companies see potential for the medicines that extends far beyond obesity. Outside of statins, she said, no medication has so dramatically reduced cardiovascular risk among people with heart disease. “The uptake of this drug is going to be skyrocketing in the next couple of years,” she said.

Persons: “ We’ve, ”, Clyde Yancy, Yuan Lu Organizations: Northwestern Medicine, American Heart Association, Yale School of Medicine Locations: Philadelphia, statins

Those diagnosed with drug-resistant TB receive medication to take for six months — a far shorter time than previously required. For decades, the standard treatment for drug-resistant TB was to take drugs daily for a year and a half, sometimes two years. Inevitably, many patients stopped taking the medicines before they were cured and ended up with more severe disease. Countries fighting TB are concerned about what may happen if that funding ends. “If our patients had to pay, we would not have one single person taking treatment,” Ms. Yahaya said.

Persons: ” Ms, Yahaya, John Green, Johnson Organizations: Global Fund, AIDS, Tuberculosis, Malaria, United Nations Locations: Ghana, India

☆ EU proposal may accelerate pharma innovation decline, industry group says
▼ + stars: | 2023-11-06 | by ( Julia Payne | ) www.reuters.com time to read: +3 min

"Any changes to our incentives system would equally affect EU-based and foreign-based companies which bring medicines to the EU and, therefore, it would not put EU firms at a disadvantage," an EU Commission spokesperson said. Medication was the single biggest contributor to the EU’s trade surplus, with 235 billion euro ($252.13 billion) worth of exports in 2021. The EFPIA said small biotech companies have already moved to the United States and China. The Commission said its proposal would reduce new medicine approval times to 180 days from 400 days. Germany, Belgium and France would be the hardest hit by the proposed rules, the EFPIA said citing research by Dolon that it commissioned.

Persons: EFPIA, Lars Fruergaard Jorgensen, Jorgensen, Ozempic, " Jorgensen, Julia Payne, Lisa Shumaker Organizations: European Commission, European Federation of Pharmaceutical Industries, EU, Commission, Novo Nordisk, Thomson Locations: BRUSSELS, United States, China, Danish, Boston, U.S, Europe, EU, Germany, Belgium, France

Search resuls for: "The Medicines"

25 mentions found